Tarsus Acquires IRenix In $75 Mln Deal; Plans To Advance IRX-101 Into Phase 3 In H1 2027

Tarsus Pharmaceuticals (TARS) agreed to acquire clinical-stage ophthalmic biopharma iRenix Medical for approximately $75 million, split evenly between $37.5 million in cash and $37.5 million in shares. The deal expands Tarsus’ ophthalmology pipeline and is likely a modest positive for investors as it adds development-stage assets at a defined entry price.

Analysis

Tarsus Pharmaceuticals (TARS) agreed to acquire clinical-stage ophthalmic biopharma iRenix Medical for approximately $75 million, split evenly between $37.5 million in cash and $37.5 million in shares. The deal expands Tarsus’ ophthalmology pipeline and is likely a modest positive for investors as it adds development-stage assets at a defined entry price.